CLASSIFICATION
Steroid Antibacterials
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Abdi Ibrahim
WAREHOUSE
International Warehouse 2
SUBSTANCE
Sodium Fusidate
What is Fucidin?
Fucidin is a powerful antibiotic specifically designed to combat a variety of staphylococcal infections caused by susceptible bacteria. It effectively treats conditions such as skin infections, osteomyelitis, pneumonia, sepsis, wound infections, endocarditis, and superinfected cystic fibrosis. When oral administration isn't feasible?especially in cases of unreliable gastrointestinal absorption?Fucidin is administered intravenously for optimal results.
Dosage and Administration
Dosage
For staphylococcal skin infections:
Adults: - Recommended dosage: 250 mg of sodium fusidate, taken twice daily for a duration of 5 to 10 days.
For more severe staphylococcal infections, such as osteomyelitis, pneumonia, sepsis, wound infections, endocarditis, and superinfected cystic fibrosis:
Adults: - Recommended dosage: 500 mg of sodium fusidate, administered three times daily.
In cases of aggressive infections, dosages may be increased or combined with additional therapies as needed. Importantly, elderly patients do not require dosage adjustments, and no changes are necessary for those with renal impairment as Fucidin is eliminated through bile. Patients undergoing hemodialysis also do not need dosage modifications, as Fucidin is minimally removed during the process.
Administration Method
Fucidin is intended for oral administration.
Special Warnings and Precautions
Caution is advised when using statins (HMG-CoA reductase inhibitors) alongside systemic Fucidin, due to reported cases of rhabdomyolysis, including fatalities. If systemic Fucidin is required, statin therapy should be paused during treatment. Patients should seek immediate medical attention if they experience muscle weakness, pain, or tenderness, with statin therapy able to resume seven days after the last dose of systemic Fucidin. In rare cases requiring prolonged systemic Fucidin treatment for severe infections, the concurrent use of statins must be carefully evaluated.
Severe skin reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, toxic epidermal necrolysis (Lyell's syndrome), and Stevens-Johnson syndrome, have been linked to systemic Fucidin. Patients should be alert for skin reactions and other symptoms during the initial weeks of treatment. If any severe reactions are suspected, Fucidin should be discontinued immediately and not reintroduced.
Fusidic acid is processed by the liver and excreted through bile, with reports of elevated liver enzymes and jaundice occurring during systemic therapy?though these effects are often reversible upon cessation. Caution is advised when administering systemic Fucidin to patients with liver dysfunction or those on potentially hepatotoxic medications; liver function should be closely monitored. Additionally, care should be taken with patients who have biliary disease or obstruction and those on HIV protease inhibitors. Fusidic acid can inhibit bilirubin binding to albumin, necessitating caution in neonates or patients with impaired bilirubin transport and metabolism due to the risk of kernicterus.
Be aware that bacterial resistance has been associated with fusidic acid use; as with all antibiotics, prolonged or repeated use can increase the risk of developing resistance. Patients with rare hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should avoid this medication due to its lactose content.